Search
Eftrenonacog alfa
go.drugbank.com/drugs/DB11608ApprovedIt was first approved by the FDA in March 2014 and later approved by the EMA in May 2016. … factor IX (FIX), leading to decreased levels of endogenous factor IX and increased susceptibility to recurrent bleeding episodes caused spontaneously or as a result of accidental or surgical trauma [FDA
Torasemide
go.drugbank.com/drugs/DB00214ApprovedInvestigational[A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]
Rituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalFDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) [L4811], however, has now been approved for a variety of conditions [FDA label]. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].
Castor oil
go.drugbank.com/drugs/DB11113ApprovedNutraceuticalVet approvedIt is an FDA-approved food additive directly added to food products for human consumption.
Bretylium
go.drugbank.com/drugs/DB01158ApprovedRecent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.
Venetoclax
go.drugbank.com/drugs/DB11581ApprovedInvestigationalVenetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. … Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries [A40022].
Terazosin
go.drugbank.com/drugs/DB01162ApprovedInvestigationalTerazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831].
Categories: Adrenergic alpha-1 Receptor AntagonistsScorpion (centruroides) immune Fab2 antivenin (equine)
go.drugbank.com/drugs/DB13905ApprovedIt was approved by FDA in 2011 and is marketed under the name Anascorp [L2196]. Anascorp is produced from equine IgG antibodies.
Ephedrine
go.drugbank.com/drugs/DB01364ApprovedInvestigational[A193701,A193704,L12975] Ephedrine was granted a type 7 FDA Approval on 29 April 2016.[L12975] … It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepinephrine from sympathetic neurons, inhibiting norepinephrine reuptake and displacing more norepinephrine
Mixtures: FLUKOL X-TRA, PIM-TRA-KOL RASA LEMONTalc
go.drugbank.com/drugs/DB09511ApprovedInvestigationalIn fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent.